Michael Baltezor

A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies

Stephen K. Williamson, Gary A. Johnson, Holly Maulhardt et al. · Cancer Chemotherapy and Pharmacology · 2015 · 64 citations · Full text

Nanoparticles, Nanomedicine, Intraperitoneal Nanoparticulate Paclitaxel +10

Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies

Jeffrey Strovel, Sitta Sittampalam, Nathan P. Coussens et al. · 2016 · 57 citations

Drug Repositioning, Oncology, Drug Target +15

<i>In silico</i> and <i>in vitro</i> drug screening identifies new therapeutic approaches for Ewing sarcoma

Ziyan Y. Pessetto, Bin Chen, Hani Alturkmani et al. · Oncotarget · 2016 · 47 citations · Full text

Drug Activity, Tumor Biology, Ewing Sarcoma +12

Tyr ¹ -ψ[( <i>Z</i> )CF═CH]-Gly ² Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin

Ryan A. Altman, Krishna K. Sharma, Lian Rajewski et al. · ACS Chemical Neuroscience · 2018 · 46 citations

Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis

Yan Ma, Michael Baltezor, Lian Rajewski et al. · Journal of Molecular Medicine · 2019 · 28 citations · Full text

Tumor Biology, Histone Deacetylase, Medicine +6